|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 康柏西普联合Ahmed引流阀植入及白内障超声乳化贯序治疗新生血管性青光眼显示文摘目的:评估玻璃体腔注射康柏西普联合Ahmed引流阀植入及白内障超声乳化吸除贯序治疗新生血管性青光眼(NVG)的疗效。方法:回顾性分析。纳入2018-06/2020-01我院眼科收治合并白内障的NVG患者18例18眼。所有患者均术前3~7d行玻璃体腔注射康柏西普,符合手术指征后进行白内障超声乳化吸除术联合Ahmed引流阀植入术,术后随访12mo,记录最佳矫正视力(BCVA)、眼压、虹膜新生血管消退情况、手术效果及并发症情况。结果:术后1、7d,1、3、6mo,1a眼压分别为25.94±11.82、15.39±4.97、15.94±2.69、15.33±4.54、18.89±7.95和16.27±5.22mmHg,均低于术前平均眼压51.44±8.18mmHg(P<0.05)。末次随访时67%(12/18)患者BCVA提高,28%(5/18)BCVA不变,1眼BCVA降低;术后1a手术完全成功15眼(83%),部分成功2眼(11%),失败1眼(6%)。结论:玻璃体腔注射康柏西普联合Ahmed引流阀植入及白内障超声乳化吸除贯序治疗合并白内障的NVG可以有效控制术后眼压,同时尽可能地提高患者BCVA,便于随诊和治疗视网膜原发疾病,可作为合并白内障的NVG治疗的有效方法。 | 王亚辰 赵丽君 | 2022 | 国际眼科杂志2022，22，5： | 6 |
| 2 | OCT参数对原发性开角型青光眼性视神经损伤的诊断价值显示文摘目的:探究频域光学相干断层成像技术(OCT)对原发性开角型青光眼性视神经损伤的诊断价值。方法:选择2018-01/2020-03我院收治的80例80眼原发性开角型青光眼患者及100例100眼健康受试者作为研究对象,将原发性开角型青光眼患者分为早期组、中期组及晚期组,采用OCT测定各组患者上方、下方、鼻侧、颞侧视乳头旁视网膜神经纤维层(pRNFL)厚度值及上方、下方黄斑区视网膜神经节细胞复合体(mGCC)厚度值,比较各组受试者OCT参数之间差异,采用Spearman相关性分析OCT参数与视野缺损程度的相关性,绘制受试者特征工作曲线(ROC)计算OCT参数诊断原发性开角型青光眼的价值。结果:入组患者早期组24例、中期组39例、晚期组17例,各组患者pRNFL、mGCC参数均有差异(P<0.05),晚期组青光眼患者上方、下方、鼻侧pRNFL、平均pRNFL及上方、下方、平均mGCC显著低于早期组、中期组,中期组患者各指标显著低于早期组(P<0.05)。Spearman相关性分析示,pRNFL、mGCC参数与原发性开角型青光眼严重程度呈负相关关系(P<0.05)。ROC曲线显示,上方pRNFL、下方pRNFL、鼻侧pRNFL、颞侧pRNFL、平均pRNFL诊断原发性开角型青光眼视神经损伤的曲线下面积为0.693、0.846、0.676、0.579、0.844,上方mGCC、下方mGCC及平均mGCC诊断原发性开角型青光眼视神经损伤的曲线下面积分别为0.542、0.677、0.676;平均pRNFL联合平均mGCC诊断原发性开角型青光眼视神经损伤的曲线下面积为0.883。结论:OCT测定pRNFL、mGCC参数与开角型青光眼视神经损伤程度密切相关,两者有较高的诊断价值,临床可将其用于诊断及病情评估。 | 陈玉敏 罗丽丹 宋卫平 张桦 | 2021 | 国际眼科杂志2021，21，4： | 4 |
| 3 | 中西医结合治疗新生血管性青光眼的效果观察显示文摘新生血管性青光眼(NVG)是一种难治性致盲性眼病,其主要诱发因素为视网膜静脉阻塞、糖尿病性视网膜病变以及眼缺血综合征等眼底缺血性病变。其不仅对患者眼体产生影响,随着病情发展会导致视力完全丧失,直接影响患者身心健康和预后效果及生活质量[1]。西医治疗作用较单一,疗效不甚满意,且刺激大,副作用多,患者依从性较差,往往不能坚持长期治疗;手术虽是主要治疗方法,但风险较大,患者存在恐惧心理。而中西医结合治疗可在降低眼压的同时改善眼动脉供血,保护视神经,降低手术风险,提高疗效[2]。本文在西医治疗基础上联合中医益肾通络明目汤治疗,疗效满意,现分析报道如下。 | 王新法 郑慧芬 周贤波 张纪卫 | 2021 | 中国中医药科技2021，28，2： | 3 |
| 4 | Comparison of complications after Ahmed versus Baerveldt implant in glaucoma patients:one year follow-up显示文摘AIM:To compare surgical results of the Ahmed and Baerveldt implant procedures in glaucoma patients at 1 y follow-up at Jakarta Eye Center(JEC)Eye Hospitals.METHODS:This cohort retrospective study was conducted on glaucoma patients aged≥18 y who had undergone Ahmed and Baerveldt implant surgery.Intraocular pressure(IOP),visual acuity,glaucoma medication,success rate,early and late postoperative complications,and the number of resurgeries were analyzed.RESULTS:A total of 351 eyes in the Ahmed group and 94 eyes in the Baerveldt group were included in this study.At 1 y follow-up,the mean IOP was found to be significantly lower in the Baerveldt group(13±4.47 mm Hg)compared to the Ahmed group(15.02±5.73 mm Hg;P=0.025).Glaucoma medication was required in both the Ahmed and Baerveldt groups(58.92%vs 71.67%).Comparable success rate was found in both groups.The Ahmed group revealed a complete and qualified success of 86.82%,and failure of 13.17%.Similarly,the Baerveldt group showed complete and qualified success in 87.75%and failure in 12.25%cases.In the Ahmed group,11.97%early complications,26.06%late complications and 9.97%resurgeries were observed.In comparison,in the Baerveldt group,23.40%early complications,30.95%late complications and 11.70%resurgeries were observed.CONCLUSION:Both groups of glaucoma implants show significant IOP reduction,however,the Baerveldt implant group demonstrates greater IOP reduction with more failure rates and complications than the Ahmed implant group. | Sara Listyani Koentjoro Widya Artini Iwan Soebijantoro Vira Wardhana Istiantoro Emma Rusmayani Rini Sulastiwaty Zeiras Eka Djamal Arini Safira Nurul Akbar Muhammad Yoserizal | 2020 | International Journal of Ophthalmology(English edition)2020，13，12： | 0 |
| 5 | Baerveldt glaucoma implant with Supramid© ripcord stent in neovascular glaucoma: a case series显示文摘AIM:To report the outcome of Baerveldt glaucoma implant(BGI)with Supramid©ripcord use in neovascular glaucoma(NVG).METHODS:We retrospectively evaluated the surgical outcome of the BGI with Supramid©3/0 ripcord stent in patients with NVG.No tube ligation or venting slits were performed.Supramid was removed after 3mo if the target intraocular pressure(IOP)was not achieved.Surgical success was defined as IOP≤21 mm Hg with(qualified success)or without IOP-lowering medications(complete success).RESULTS:Twenty-six eyes from 24 patients were included in the study.The median duration of follow-up was 4[interquartile range(IQR)=1-5]y,ranging from 0.5 to 5y.IOP decreased by a mean of 24.2 mm Hg(59.7%);from a mean of 40.5±12.6 mm Hg at baseline to 16.3±11.9 mm Hg,P≤0.001.The number of glaucoma medications reduced from a median of 5(IQR=5-6)to 1(IQR=0-2,P≤0.001)at the final follow-up.Overall success rates were 88.0%at 1y,34.8%at 3y,66.7%at 4y,and 50%at 5y.Hypertensive phase(HP)in the first 3mo occurred in 15/26 eyes(57.7%)with a mean IOP of 31.1 mm Hg.CONCLUSION:BGI with Supramid©ripcord stent gives close to 90%of the overall survival rate at the final follow-up without significant early hypotony.However,early HP is still a challenge. | Yuen Keat Gan Shiivaa Manjare Birapadian Muhammad Irfan Abdul Jalal Norshamsiah Md Din | 2024 | International Journal of Ophthalmology(English edition)2024，17，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员